



PRESS RELEASE DECEMBER 13th, 2010

MOBERG DERMA WITHDRAWS ITS IPO

The board of directors of Moberg Derma AB (publ.) has decided to withdraw the proposed listing on NASDAQ OMX Stockholm, as the demand from investors was not sufficient to ensure a successful post IPO life on the stock exchange.

"We have experienced great interest from investors in Moberg Derma as a company. However, we and our advisors have underestimated the climate for initial public offerings and listings and the willingness to subscribe for shares has not been sufficient. As a consequence, we do not have the shareholder base needed to ensure a successful listing", says Peter Wolpert, Moberg Derma's CEO and founder, and continues: "By the financial means we have since before, we will now continue to develop Moberg Derma, as a non-listed company, with focus on additional market launches and prioritized development projects."

E. Öhman J:or Fondkommission AB has been the financial advisor and Advokatfirman Lindahl KB has been the legal advisor of Moberg Derma with relation to the new issue and listing of the company's shares on NASDAQ OMX Stockholm. Avanza Bank AB and Nordnet Bank AB have been retail-distributors in the offer.

For further information, please contact:

Peter Wolpert, CEO of Moberg Derma

Telephone: +46 8 522 307 00

Mobile: +46 735 71 35

E-mail: peter.wolpert@mobergderma.se

About Moberg Derma

Moberg Derma AB (publ.), based in Stockholm, develops patented topical pharmaceuticals for the treatment of common disorders through the use of innovative drug delivery. The company's products are based on proven compounds, which reduce time to market, development costs and risk. The portfolio covers projects in the preclinical phase to approved and launched products. The company began operations at the Karolinska Institute in Stockholm in 2006. Moberg Derma is owned by institutional and private investors, Board and management.

For further information, please visit: www.mobergderma.se